Conflict Minerals Disclosure
Navidea Biopharmaceuticals, Inc. (the Company) has evaluated its current product line to determine whether it manufactures or contracts to manufacture any products for which columbite tantalite (colta), cassiterite, gold, wolframite, or their derivatives are necessary to the functionality of the product. The Company has determined that its Lymphoseek® (technetium Tc 99m tilmanocept) Injection product (the Covered Product) contains tin, a derivative metal from the mineral cassiterite.
The Company has conducted a reasonable country of origin inquiry (RCOI) as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Company’s RCOI consisted of submitting inquiries to its supplier of the covered product. The Company has relied on the certification from an upstream supplier of its supplier that the tin used in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country. The Company has no reason to believe that this certification is inaccurate. Accordingly, the Company has determined that the tin contained in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country.